Express News | Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
BenzingaApr 30 07:32 ET
Express News | Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)
ReutersApr 30 07:30 ET
Express News | Hearing Tenax Therapeutics To Be Issued U.S. Patent Titled 'LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION'
BenzingaApr 29 15:15 ET
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation (NYSE:AA) rose sharply in today's pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of
BenzingaApr 18 06:28 ET
Tenax Therapeutics to Host KOL Event: "LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study"
Presentations from four globally recognized experts in the field of heart failure will explore this most prevalent type of pulmonary hypertension and the therapeutic potential of levosimendan:
Globe NewswireApr 9 08:30 ET
Tenax Therapeutics: Q4 Earnings Insights
Tenax Therapeutics (NASDAQ:TENX) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM.Here's what investors need to know about the announcement.EarningsTenax Therapeutics missed es
BenzingaMar 28 17:05 ET
Express News | Tenax Therapeutics Q4 EPS $(11.84) Misses $(8.14) Estimate
Moomoo 24/7Mar 28 17:01 ET
Tenax Therapeutics GAAP EPS of -$31.04
Seeking AlphaMar 28 08:44 ET
Tenax Therapeutics 2023 Loss $7.7M >TENX
Tenax Therapeutics 2023 Loss $7.7M >TENX
Dow JonesMar 28 08:39 ET
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that
GlobeNewswireMar 12 08:30 ET
Tenax Therapeutics Meets Nasdaq's Float Requirement Compliance
TipRanksFeb 24 10:06 ET
Express News | Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $30 Price Target
Moomoo 24/7Feb 20 11:59 ET
Tenax Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 644.44% Roth MKM → $30 Reiterates Buy → Buy 11/13/2023 48.89% Roth MKM → $6 Reiterates Buy → Bu
BenzingaFeb 20 11:56 ET
Tenax Secures Global Rights for Heart Treatment Drug
InvestingFeb 20 09:12 ET
Express News | Tenax Therapeutics Announces Amendment To Existing Exclusive License Agreement With Orion Corporation, Expanding Tenax's Territory Rights From North America To The Entire World
Moomoo 24/7Feb 20 08:32 ET
Express News | Tenax Therapeutics 13G Filing Shows CVI Investments, Inc. Reported A 9.9% Stake In The Co As Of February 8, 2024
Moomoo 24/7Feb 16 12:45 ET
Tenax Therapeutics Raises $9M in Public Offering and Warrants
TipRanksFeb 12 17:04 ET
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.13%
InvestingFeb 8 16:30 ET
Top Midday Decliners
Tenax Therapeutics (TENX) said Thursday it priced an offering of 1.6 million shares and warrants to purchase up to 3.2 million shares at $5.65 per share and associated common warrant, targeting gross
MT NewswiresFeb 8 13:56 ET
Why Tenax Therapeutics (TENX) Stock Is Getting Obliterated
Tenax Therapeutics Inc (NASDAQ:TENX) shares are trading lower by 64.3% to $5.08 Thursday morning after the company announced the pricing of a public offering involving the sale of 1.6 million shares o
BenzingaFeb 8 11:20 ET
No Data
No Data